2021
Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response
Hajiran A, Chakiryan N, Aydin A, Zemp L, Nguyen J, Laborde J, Chahoud J, Spiess P, Zaman S, Falasiri S, Fournier M, Teer J, Dhillon J, McCarthy S, Moran-Segura C, Katende E, Sexton W, Koomen J, Mulé J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clinical & Experimental Immunology 2021, 204: 96-106. PMID: 33346915, PMCID: PMC7944355, DOI: 10.1111/cei.13567.Peer-Reviewed Original ResearchConceptsMetastatic clear cell renal cell carcinomaClear cell renal cell carcinomaTumor immune microenvironmentRenal cell carcinomaT-betOverall survivalCell carcinomaMetastatic renal cell carcinomaForkhead box protein 3Improved overall survivalCell renal cell carcinomaCox regression analysisImmune cell distributionT-cell markersPoor overall survivalBox protein 3Tumor-stromal interfaceMetastatic tumor samplesPrecision treatment strategiesTumor-stroma interfaceTumor coreImproved survivalImmune markersImmunotherapy responsePoor outcome
2020
MP14-03 DENSITY OF T-BET POSITIVE T LYMPHOCYTES WITHIN THE TUMOR MICROENVIRONMENT IS ASSOCIATED WITH A FAVORABLE RESPONSE TO IMMUNOTHERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Hajiran* A, Aydin A, Kim Y, Zemp L, McCarthy S, Segura C, Nguyen J, Falasiri S, Zaman S, Spiess P, Kohli M, Mulé J, Manley B. MP14-03 DENSITY OF T-BET POSITIVE T LYMPHOCYTES WITHIN THE TUMOR MICROENVIRONMENT IS ASSOCIATED WITH A FAVORABLE RESPONSE TO IMMUNOTHERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000839.03.Peer-Reviewed Original ResearchPD39-06 POOR RESPONSE TO IMMUNOTHERAPY IS ASSOCIATED WITH HIGH EXPRESSION OF A NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR SPLICE VARIANT IN PATIENTS WITH RENAL CELL CARCINOMA
Hajiran* A, Kim Y, Zaman S, Madanyake T, Robinson T, Falasiri S, Spiess P, Kohli M, Boyle T, Mulé J, Teer J, Manley B. PD39-06 POOR RESPONSE TO IMMUNOTHERAPY IS ASSOCIATED WITH HIGH EXPRESSION OF A NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR SPLICE VARIANT IN PATIENTS WITH RENAL CELL CARCINOMA. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000918.06.Peer-Reviewed Original Research
2019
Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy
Zaman S, Hajiran A, Coba GA, Robinson T, Madanayake TW, Segarra DT, Chobrutskiy BI, Boyle TA, Zhou JM, Kim Y, Mulé JJ, Teer JK, Manley BJ. Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. European Urology Focus 2019, 7: 373-380. PMID: 31901438, PMCID: PMC7771328, DOI: 10.1016/j.euf.2019.12.001.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell renal cell carcinomaClear cell renal cell carcinomaCell carcinomaPoor responseAdvanced clear cell renal cell carcinomaTumor tissueNon-RCC tumorsCohort of patientsRCC tumor tissuesReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionFrequent somatic alterationsKidney cancer cell linesAdvanced ccRCCCancer cell linesCancer Genome AtlasSystemic therapyClinical outcomesInstitutional cohortPatient populationPoor prognosisHuman kidney cancer cell linesClinical significanceTCGA cohort